Orphan Drugs Market Access and Regulatory Affairs 2014

Many blockbuster drugs will lose their exclusivity in the next five years. Therefore, the current economic situation has shifted the focus of many pharmaceutical companies from essential medicines to orphan drugs.

> Hear about the Latest Trends and Developments in Orphan Drugs Legislation
> Learn about Early Access to Orphan Drugs for Patients with Unmet Medical Need
> Discuss Orphan-Drug Designations and Marketing Approvals in the New Millennium and FDA and EMA Experiences
> Explore the Regulatory Landscape for Orphan Drug Development in order to Anticipate Future Changes

> Early access to Orphan Drugs for patients with unmet medical need
> Patient Centered Approach Seen by Patients
> Orphan Drug Designations and Marketing Approvals in the New Millennium
> Road from R&D to Market and more

SPEAKER PANEL
Dr. Carlos R. Camozzi,JuSpeaker Juan Fuertes,Mark Corbett,Cecil Nick, Diego Ardigo